JP2004508280A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004508280A5 JP2004508280A5 JP2001556226A JP2001556226A JP2004508280A5 JP 2004508280 A5 JP2004508280 A5 JP 2004508280A5 JP 2001556226 A JP2001556226 A JP 2001556226A JP 2001556226 A JP2001556226 A JP 2001556226A JP 2004508280 A5 JP2004508280 A5 JP 2004508280A5
- Authority
- JP
- Japan
- Prior art keywords
- apc
- use according
- protein
- disease
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940096437 Protein S Drugs 0.000 description 5
- 102000029301 Protein S Human genes 0.000 description 5
- 108010066124 Protein S Proteins 0.000 description 5
- 206010010904 Convulsion Diseases 0.000 description 3
- 101800004937 Protein C Proteins 0.000 description 3
- 102000017975 Protein C Human genes 0.000 description 3
- 101800001700 Saposin-D Proteins 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229960000856 protein c Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000002981 neuropathic effect Effects 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000003959 neuroinflammation Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18022700P | 2000-02-04 | 2000-02-04 | |
| PCT/US2001/003758 WO2001056532A2 (en) | 2000-02-04 | 2001-02-05 | Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein c (apc) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004508280A JP2004508280A (ja) | 2004-03-18 |
| JP2004508280A5 true JP2004508280A5 (OSRAM) | 2008-03-27 |
Family
ID=22659693
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001556226A Pending JP2004508280A (ja) | 2000-02-04 | 2001-02-05 | 活性化プロテインｃ（ａｐｃ）の神経保護薬、抗血栓薬および抗炎症薬としての使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7074402B2 (OSRAM) |
| EP (1) | EP1255556B1 (OSRAM) |
| JP (1) | JP2004508280A (OSRAM) |
| AT (1) | ATE504310T1 (OSRAM) |
| AU (1) | AU2001238034A1 (OSRAM) |
| CA (1) | CA2398929C (OSRAM) |
| DE (1) | DE60144366D1 (OSRAM) |
| WO (1) | WO2001056532A2 (OSRAM) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040096443A1 (en) * | 2002-03-08 | 2004-05-20 | Traynelis Stephen Francis | Treatment of neurodegenerative diseases and conditions using par1 antagonists |
| ATE550073T1 (de) | 2001-06-13 | 2012-04-15 | Univ Sydney | Protein c für die wundheilung |
| US20030073636A1 (en) * | 2001-09-19 | 2003-04-17 | Oklahoma Medical Research Foundation | Method of treating diabetes |
| CA2499458C (en) * | 2002-09-30 | 2013-11-12 | Socratech L.L.C. | Protein s protects the nervous system from injury |
| CA2508276C (en) * | 2002-12-05 | 2018-03-27 | Socratech L.L.C. | Neuroprotective activity of activated protein c is independent of its anticoagulant activity |
| WO2004056309A2 (en) * | 2002-12-05 | 2004-07-08 | Socratech L.L.C. | Neuroprotective activity of activated protein c is independent of its anticoagulant activity |
| US20070142272A1 (en) * | 2003-01-24 | 2007-06-21 | Zlokovic Berislav V | Neuroprotective activity of activated protein c independent of its anticoagulant activity |
| US9192657B2 (en) * | 2003-07-08 | 2015-11-24 | The Scripps Research Institute | Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity |
| CA2574598A1 (en) * | 2004-07-23 | 2006-02-09 | The University Of Rochester | Activated protein c inhibits undesirable effects of plasminogen activator in the brain |
| US20080293631A1 (en) * | 2005-01-07 | 2008-11-27 | Christopher John Jackson | Treatment for Autoimmune and Inflammatory Conditions |
| US7785857B2 (en) * | 2006-08-31 | 2010-08-31 | Saint Louis University | Protein C variant |
| AU2008280782B2 (en) | 2007-07-20 | 2014-01-23 | Diamedica Inc. | Tissue kallikrein for the treatment of diseases associated with amyloid protein |
| WO2009099642A2 (en) * | 2008-02-05 | 2009-08-13 | The Board Of Trustees Of The Leland Stanford Junior University | Proteomic analysis of active multiple sclerosis lesions |
| CN102458454A (zh) * | 2009-04-22 | 2012-05-16 | 森诺姆尼有限公司 | 用于治疗亨廷顿病的组织激肽释放酶 |
| US20150150954A1 (en) | 2012-07-04 | 2015-06-04 | The University Of Sydney | Treatment of inflammatory skin disorders |
| CN104122396A (zh) * | 2013-04-23 | 2014-10-29 | 中国科学院上海生命科学研究院 | 维生素k依赖性蛋白s作为糖尿病标志物的应用 |
| DK3137102T3 (da) | 2014-04-16 | 2021-10-11 | Zz Biotech Llc | Apc til anvendelse til behandling af unormal kutan ardannelse |
| ES2890623T3 (es) | 2014-04-16 | 2022-01-20 | Zz Biotech Llc | Uso del análogo de APC para curar heridas |
| CN105806818B (zh) * | 2016-04-01 | 2019-11-22 | 南京医科大学 | 检测血小板nmda受体活性的方法及其应用 |
| WO2017212476A1 (en) | 2016-06-05 | 2017-12-14 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Novel molecules for the treatment of inflammation |
| KR20190122706A (ko) | 2017-03-09 | 2019-10-30 | 다이어메디카 인코포레이티드 | 조직 칼리크레인 1의 투약 형태 |
| CA3176941A1 (en) * | 2020-03-24 | 2021-09-30 | Talengen International Limited | Method and medicine for treating huntington's disease |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5084274A (en) * | 1987-11-17 | 1992-01-28 | Scripps Clinic And Research Foundation | Inhibition of arterial thrombotic occlusion or thromboembolism |
| US5009889A (en) * | 1987-12-31 | 1991-04-23 | Oklahoma Medical Research Foundation | Treatment of dysfunctional vascular endothelium using activated protein C |
| AT402153B (de) * | 1989-06-26 | 1997-02-25 | Immuno Ag | Protein-s-hältige pharmazeutische präparation |
| US5254532A (en) * | 1989-06-26 | 1993-10-19 | Immuno Aktiengesellschaft Fur Chemisch-Medizinische Produkte | Preparation for treating and preventing thromboses and thromboembolic complications, use of such a preparation and a method of producing the same |
| IL131615A0 (en) * | 1997-03-24 | 2001-01-28 | Lilly Co Eli | Methods for treating vascular disorders |
| CN1265598A (zh) * | 1997-06-05 | 2000-09-06 | 伊莱利利公司 | 治疗血栓形成性疾病的方法 |
| HUP0001237A3 (en) * | 1997-10-20 | 2002-01-28 | Lilly Co Eli | Methods for treating vascular disorders |
-
2001
- 2001-02-05 US US09/777,484 patent/US7074402B2/en not_active Expired - Fee Related
- 2001-02-05 DE DE60144366T patent/DE60144366D1/de not_active Expired - Lifetime
- 2001-02-05 WO PCT/US2001/003758 patent/WO2001056532A2/en not_active Ceased
- 2001-02-05 CA CA2398929A patent/CA2398929C/en not_active Expired - Fee Related
- 2001-02-05 AT AT01910427T patent/ATE504310T1/de not_active IP Right Cessation
- 2001-02-05 AU AU2001238034A patent/AU2001238034A1/en not_active Abandoned
- 2001-02-05 JP JP2001556226A patent/JP2004508280A/ja active Pending
- 2001-02-05 EP EP01910427A patent/EP1255556B1/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004508280A5 (OSRAM) | ||
| Seal et al. | Intracameral sustained-release bimatoprost implant delivers bimatoprost to target tissues with reduced drug exposure to off-target tissues | |
| WO2009104932A3 (ko) | 복합제제 | |
| US6359005B1 (en) | Method for the treatment of mania and bipolar disorder | |
| JP2007514750A5 (OSRAM) | ||
| CA2492081A1 (en) | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders | |
| CA2533332A1 (en) | Therapeutic compounds | |
| JP2002532392A5 (OSRAM) | ||
| JP2005501110A5 (OSRAM) | ||
| JP5680412B2 (ja) | レオヌリンの使用およびその組成物 | |
| JP2002530353A5 (OSRAM) | ||
| JP2010531861A (ja) | パーキンソン病治療薬 | |
| JP2010531862A (ja) | パーキンソン病治療薬 | |
| Katsuta et al. | The neuroprotective effect of the novel noncompetitive NMDA antagonist, FR115427 in focal cerebral ischemia in rats | |
| RU2674653C2 (ru) | Способ предотвращения и/или лечения хронической травматической энцефалопатии - ii | |
| Rosenow et al. | Recent and future advances in the treatment of status epilepticus | |
| JP2012502105A5 (OSRAM) | ||
| Komatsu et al. | Effect of hemoglobin vesicle, a cellular-type artificial oxygen carrier, on middle cerebral artery occlusion-and arachidonic acid-induced stroke models in rats | |
| Shoulson et al. | Clonidine and the anti-parkinsonian response to L-DOPA or piribedil | |
| Graves et al. | Drug‐Induced Toxicities Associated with High‐Dose Cytosine Arabinoside Infusions | |
| CN105451727A (zh) | 用于预防和/或治疗i型慢性创伤性脑病的方法 | |
| DE602004012152T2 (de) | Verwendung von cystin oder cystein zur vorbeugung und behandlung von oxidativem stress hervorgerufen durch hämodialyse bei patienten mit chronischen nierenerkrankungen | |
| TWI474825B (zh) | 治療神經損傷之醫藥套組 | |
| JPH06263636A (ja) | 脳または高次神経疾患治療剤 | |
| Koshy et al. | Thiopentone–midazolam mixture as an induction agent for general anasthesia on ‘in-patients’ |